Concepts (137)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Intensive Care Units | 9 | 2024 | 266 | 3.210 |
Why?
|
Critical Illness | 7 | 2023 | 126 | 3.110 |
Why?
|
Sepsis | 6 | 2020 | 119 | 2.620 |
Why?
|
Critical Care | 6 | 2024 | 180 | 2.460 |
Why?
|
Physicians | 3 | 2021 | 112 | 1.880 |
Why?
|
Family | 4 | 2024 | 94 | 1.690 |
Why?
|
Immunocompromised Host | 2 | 2018 | 39 | 1.120 |
Why?
|
Hospital Mortality | 3 | 2020 | 131 | 1.090 |
Why?
|
Anxiety | 3 | 2023 | 150 | 1.040 |
Why?
|
Neoplasms | 2 | 2020 | 224 | 0.980 |
Why?
|
Staphylococcal Infections | 4 | 2020 | 144 | 0.980 |
Why?
|
Depression | 3 | 2023 | 412 | 0.870 |
Why?
|
Communication | 2 | 2023 | 119 | 0.800 |
Why?
|
Stress, Psychological | 2 | 2021 | 211 | 0.790 |
Why?
|
Humans | 22 | 2024 | 25692 | 0.770 |
Why?
|
Palliative Medicine | 1 | 2021 | 6 | 0.760 |
Why?
|
Adult | 12 | 2022 | 7336 | 0.700 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2023 | 201 | 0.690 |
Why?
|
Patient Advocacy | 1 | 2019 | 12 | 0.660 |
Why?
|
Hematologic Neoplasms | 2 | 2016 | 18 | 0.660 |
Why?
|
HIV Infections | 2 | 2016 | 457 | 0.630 |
Why?
|
Tracheostomy | 1 | 2018 | 23 | 0.620 |
Why?
|
Hospitals, Low-Volume | 1 | 2018 | 6 | 0.620 |
Why?
|
Hospitals, High-Volume | 1 | 2018 | 8 | 0.620 |
Why?
|
Ventilator Weaning | 1 | 2018 | 34 | 0.610 |
Why?
|
Bacteremia | 3 | 2020 | 94 | 0.610 |
Why?
|
Staphylococcus aureus | 2 | 2018 | 63 | 0.590 |
Why?
|
Patient Care Team | 1 | 2019 | 130 | 0.580 |
Why?
|
Chronic Disease | 1 | 2019 | 403 | 0.580 |
Why?
|
Middle Aged | 12 | 2021 | 8403 | 0.560 |
Why?
|
Organ Dysfunction Scores | 1 | 2016 | 8 | 0.540 |
Why?
|
Immunologic Deficiency Syndromes | 1 | 2016 | 8 | 0.520 |
Why?
|
Respiration, Artificial | 3 | 2021 | 101 | 0.490 |
Why?
|
Rheumatic Diseases | 1 | 2016 | 47 | 0.490 |
Why?
|
Immunosuppressive Agents | 1 | 2016 | 124 | 0.480 |
Why?
|
Aged | 10 | 2021 | 8501 | 0.460 |
Why?
|
Decision Making | 3 | 2021 | 203 | 0.460 |
Why?
|
Immune System Diseases | 1 | 2014 | 1 | 0.450 |
Why?
|
Male | 12 | 2021 | 13917 | 0.450 |
Why?
|
Female | 12 | 2021 | 14273 | 0.440 |
Why?
|
Algorithms | 1 | 2016 | 347 | 0.430 |
Why?
|
Pandemics | 2 | 2021 | 227 | 0.330 |
Why?
|
Cross Infection | 1 | 2011 | 253 | 0.320 |
Why?
|
Hospitalization | 3 | 2021 | 292 | 0.300 |
Why?
|
Retrospective Studies | 6 | 2018 | 3220 | 0.300 |
Why?
|
Surveys and Questionnaires | 2 | 2021 | 1077 | 0.260 |
Why?
|
Prognosis | 2 | 2020 | 739 | 0.260 |
Why?
|
Chicago | 2 | 2019 | 869 | 0.250 |
Why?
|
Influenza, Human | 2 | 2016 | 39 | 0.250 |
Why?
|
Length of Stay | 2 | 2018 | 300 | 0.250 |
Why?
|
Age Factors | 2 | 2018 | 716 | 0.240 |
Why?
|
Proportional Hazards Models | 2 | 2018 | 332 | 0.240 |
Why?
|
Severity of Illness Index | 2 | 2018 | 913 | 0.220 |
Why?
|
Policy | 1 | 2023 | 7 | 0.220 |
Why?
|
Consensus | 1 | 2023 | 90 | 0.210 |
Why?
|
Morals | 1 | 2021 | 4 | 0.190 |
Why?
|
Aged, 80 and over | 3 | 2019 | 4459 | 0.180 |
Why?
|
Sleep | 1 | 2024 | 316 | 0.180 |
Why?
|
Immunity | 1 | 2020 | 15 | 0.180 |
Why?
|
Body Temperature | 1 | 2020 | 44 | 0.180 |
Why?
|
Palliative Care | 1 | 2021 | 99 | 0.180 |
Why?
|
Cytokines | 2 | 2020 | 212 | 0.180 |
Why?
|
Health Personnel | 1 | 2021 | 102 | 0.170 |
Why?
|
Uncertainty | 1 | 2020 | 5 | 0.170 |
Why?
|
Logistic Models | 2 | 2018 | 366 | 0.170 |
Why?
|
Prospective Studies | 2 | 2021 | 1633 | 0.170 |
Why?
|
Professional-Family Relations | 1 | 2019 | 25 | 0.170 |
Why?
|
Multilevel Analysis | 1 | 2018 | 7 | 0.160 |
Why?
|
Risk Factors | 3 | 2015 | 2224 | 0.150 |
Why?
|
Lymphocyte Count | 1 | 2018 | 14 | 0.150 |
Why?
|
Th2 Cells | 1 | 2018 | 15 | 0.150 |
Why?
|
Th1 Cells | 1 | 2018 | 23 | 0.150 |
Why?
|
Th17 Cells | 1 | 2018 | 25 | 0.150 |
Why?
|
Statistics, Nonparametric | 1 | 2018 | 119 | 0.150 |
Why?
|
Flow Cytometry | 1 | 2018 | 107 | 0.150 |
Why?
|
United States | 2 | 2021 | 1943 | 0.150 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2018 | 29 | 0.150 |
Why?
|
Odds Ratio | 1 | 2018 | 244 | 0.140 |
Why?
|
Socioeconomic Factors | 1 | 2018 | 277 | 0.140 |
Why?
|
Sex Factors | 1 | 2018 | 427 | 0.140 |
Why?
|
Pilot Projects | 1 | 2018 | 392 | 0.140 |
Why?
|
Quality of Life | 1 | 2021 | 600 | 0.140 |
Why?
|
APACHE | 1 | 2016 | 26 | 0.140 |
Why?
|
Case-Control Studies | 1 | 2018 | 532 | 0.140 |
Why?
|
Body Mass Index | 1 | 2018 | 419 | 0.130 |
Why?
|
Virus Diseases | 1 | 2016 | 9 | 0.130 |
Why?
|
ROC Curve | 1 | 2016 | 129 | 0.130 |
Why?
|
Coinfection | 1 | 2016 | 19 | 0.130 |
Why?
|
International Classification of Diseases | 1 | 2016 | 12 | 0.130 |
Why?
|
Organ Transplantation | 1 | 2016 | 22 | 0.130 |
Why?
|
Bacterial Infections | 1 | 2016 | 41 | 0.130 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2015 | 17 | 0.120 |
Why?
|
Time Factors | 1 | 2018 | 1336 | 0.120 |
Why?
|
Databases, Factual | 1 | 2016 | 329 | 0.110 |
Why?
|
NF-E2-Related Factor 2 | 1 | 2013 | 1 | 0.110 |
Why?
|
Antioxidant Response Elements | 1 | 2013 | 1 | 0.110 |
Why?
|
Pulmonary Alveoli | 1 | 2013 | 20 | 0.110 |
Why?
|
Oxidative Stress | 1 | 2013 | 93 | 0.100 |
Why?
|
Georgia | 1 | 2011 | 9 | 0.100 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2011 | 60 | 0.090 |
Why?
|
Community-Acquired Infections | 1 | 2011 | 61 | 0.090 |
Why?
|
HIV-1 | 1 | 2013 | 221 | 0.090 |
Why?
|
Acute Disease | 1 | 2011 | 187 | 0.090 |
Why?
|
Infant | 2 | 2016 | 529 | 0.060 |
Why?
|
Child, Preschool | 2 | 2016 | 640 | 0.050 |
Why?
|
Infant, Newborn | 2 | 2016 | 588 | 0.050 |
Why?
|
Treatment Outcome | 1 | 2011 | 3231 | 0.050 |
Why?
|
Child | 2 | 2016 | 1277 | 0.050 |
Why?
|
Fever | 1 | 2020 | 30 | 0.040 |
Why?
|
Shock, Septic | 1 | 2020 | 57 | 0.040 |
Why?
|
Adolescent | 2 | 2016 | 2076 | 0.040 |
Why?
|
Young Adult | 2 | 2016 | 1855 | 0.040 |
Why?
|
Survival Analysis | 1 | 2016 | 246 | 0.030 |
Why?
|
Influenza Vaccines | 1 | 2015 | 10 | 0.030 |
Why?
|
Age Distribution | 1 | 2015 | 84 | 0.030 |
Why?
|
Antiviral Agents | 1 | 2015 | 66 | 0.030 |
Why?
|
Hospitals | 1 | 2015 | 143 | 0.030 |
Why?
|
Comorbidity | 1 | 2015 | 457 | 0.030 |
Why?
|
Quinones | 1 | 2013 | 1 | 0.030 |
Why?
|
NAD(P)H Dehydrogenase (Quinone) | 1 | 2013 | 1 | 0.030 |
Why?
|
Tight Junction Proteins | 1 | 2013 | 1 | 0.030 |
Why?
|
Sulfoxides | 1 | 2013 | 3 | 0.030 |
Why?
|
Incidence | 1 | 2016 | 731 | 0.030 |
Why?
|
Thiocyanates | 1 | 2013 | 2 | 0.030 |
Why?
|
Zonula Occludens-1 Protein | 1 | 2013 | 7 | 0.030 |
Why?
|
Isothiocyanates | 1 | 2013 | 3 | 0.030 |
Why?
|
Glutathione | 1 | 2013 | 18 | 0.030 |
Why?
|
Occludin | 1 | 2013 | 8 | 0.030 |
Why?
|
Claudins | 1 | 2013 | 6 | 0.030 |
Why?
|
Rats, Transgenic | 1 | 2013 | 17 | 0.030 |
Why?
|
Anticarcinogenic Agents | 1 | 2013 | 16 | 0.030 |
Why?
|
RNA Interference | 1 | 2013 | 32 | 0.030 |
Why?
|
Down-Regulation | 1 | 2013 | 94 | 0.030 |
Why?
|
RNA, Messenger | 1 | 2013 | 284 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2013 | 495 | 0.020 |
Why?
|
Rats | 1 | 2013 | 649 | 0.020 |
Why?
|
Animals | 1 | 2013 | 3510 | 0.020 |
Why?
|